Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of MDGN201 TARGTEPO in CKD/ESRD Anemia
NCT02117427Phase 2Completed
- Sponsor
- Avalo Therapeutics
- Start
- May 2014
- Primary completion
- Jun 2016
- Modality
- Gene Editing, Gene Silencing, Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of MDGN201 in anemia (3 arms), sponsored by Avalo Therapeutics. Primary endpoints: Total EPO Secretion up to 52 weeks, Percent (%) of Hb Measurements After Implantation Within 9-11 g/dL at 52 weeks and 1 more. Started May 2014; status: completed.
02
Drugs
MDGN201
03
Conditions
anemia
Beyond the preview
Go deeper on NCT02117427.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02117427.